Bart Vanhaesebroeck (Ludwig Institute for Cancer Research, London, UK)

10:00 - 10:15

Introduction

Mike Waterfield (Ludwig Institute for Cancer Research, London, UK)

10:15 - 10:45

PI3K in lymphocytes: isoform specificity, downstream targets and role in leukemia

David Fruman (Irvine, CA, USA)

10:45 - 11:15

A role of p85alpha in lymphocyte development

Shigeo Koyasu (Tokyo, Japan)

11:15 - 11:45

Btk-dependent regulation of phosphoinositide synthesis

Chris Carpenter (Boston, MA, USA)

11:45 - 12:00

Intrinsic protein kinase activity as a mechanism of PI 3-kinase regulation in vivo

Lazaros Foukas (Ludwig Institute for Cancer Research, London, UK)

12:00 - 12:30

PI3K in T cell activation and differentiation

Klaus Okkenhaug (Babraham Institute, Cambridge, UK)

Stephen Ward (Bath, UK)

10:00 - 10:15

Introduction

Mike Waterfield (Ludwig Institute for Cancer Research, London, UK)

13:30 - 13:45

Visualization of PI 3-kinase signalling in cells

Glen Prestwich (Echelon Biosciences Inc., USA)

13:45 - 14:15

Phosphoinositides in chemotaxis

Takehiko Sasaki - sponsored by Boehringer Ingelheim (Akita, Japan)

14:15 - 14:45

Acute regulation of the tumour suppressor phosphatase, PTEN by anionic lipids and reactive oxygen species

Peter Downes (Dundee, UK)

14:45 - 15:15

The PTEN tumor suppressor : involvement of a tumor suppressor candidate in PTEN turnover

Tomohiko Maehama (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

15:15 - 15:30

PKB/Akt activation by PTEN inhibitors and PI 3-kinase activators

Rudiger Woscholski (Imperial College London, UK)

16:00 - 16:15

The role of phosphoinositide dependent kinase 1 (PDK1) in T lymphocytes

Heather Hinton (Dundee, UK)

16:15 - 16:45

Physiological functions of PKB/Akt

Brian Hemmings (Freidrich Meischer Research Institute, Basel, Switzerland)

16:45 - 17:15

Identification and validation of novel cancer targets that act downstream of PI 3-kinase

Anke Klippel (Atugen AG, Germany)

Melanie Welham (Bath, UK)

09:30 - 10:00

The role of PI 3-kinase in cell transformation

Lew Cantley (Boston, MA, USA)

10:00 - 10:30

PI3K signalling and Tuberous Sclerosis Complex (TSC): the S6K connection

Richard Lamb (Institute for Cancer Research, London, UK)

10:30 - 10:45

Phosphoinositide 3-kinase and forkhead, a switch for cell division

Ana Carrera (Centro Nacional de Biotecnologia, Madrid, Spain)

11:15 - 11:45

Functional analysis of a tumor suppressor gene, PTEN in various tissues

Akira Suzuki (Akita, Japan)

11:45 - 12:15

Inhibiting the PI3K pathway for cancer treatment

Paul Workman (Cancer Research UK Centre for Cancer Therapeutics, London, UK)

Peter Finan (Novartis Horsham Research Centre, UK)

13:15 - 13:45

Role of the class IA PI3K isoform delta in disease

Joel Hayflick (ICOS, Bothell, WA, USA)

13:45 - 14:15

Chemokine inhibition ¿ why, when, where, which and how?

Christian Rommel (Serono, Geneva, Switzerland)

14:15 - 14:30

Who is who in mast cell function? - Store-operated Ca²⁺ entry and protein kinase C take a new role upstream of PI3K

Katja Björklöf (Fribourg, Switzerland)

14:30 - 14:45

P-Rex1-deficient mice have impaired neutrophil function

Heidi Welch (The Babraham Institute, Cambridge, UK)

15:15 - 15:45

The role of PI3K in murine neutrophil chemotaxis during airway inflammation

Peter Finan (Novartis Horsham Research Centre, UK)

15:45 - 16:15

PI3Kgamma: kinase-dependent and independent activities in cardiovascular function and disease

Emilio Hirsch (Torino, Italy)

16:15 - 16:45

Phosphoinositide 3-kinase: a novel target for anti-thrombotic therapy

Shaun Jackson (Australian Centre for Blood Diseases, Victoria, Australia)